Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.41 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | NSD2 | O96028 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3811770 | 0.92 | KMT2A (0.45) | KMT2AMEN1ALDH1A1HPGDLIMK2 | |
| SCHEMBL3809057 | 0.87 | HDAC1 (0.52) | KMT2AMEN1ALDH1A1HPGDLIMK2 | |
| SCHEMBL3815269 | 0.85 | NSD2 (0.45) | KMT2AMEN1ATMKDM1ANSD2 | |
| SCHEMBL3810933 | 0.80 | KMT2A (0.48) | KMT2AMEN1ALDH1A1HPGDLIMK2 | |
| SCHEMBL13839364 | 0.80 | NSD2 (0.46) | KMT2AMEN1ALDH1A1HPGDHTT | |
| SCHEMBL3815252 | 0.80 | HDAC1 (0.51) | KMT2AMEN1ALDH1A1HPGDLIMK2 | |
| SCHEMBL3819100 | 0.79 | KMT2A (0.44) | KMT2AMEN1ALDH1A1HPGDLIMK2 | |
| SCHEMBL3809571 | 0.79 | KMT2A (0.42) | KMT2AMEN1ALDH1A1HPGDLIMK2 | |
| SCHEMBL3815532 | 0.79 | NSD2 (0.47) | KMT2AMEN1ALDH1A1HTTPDK1 | |
| SCHEMBL3813497 | 0.78 | SMN1; SMN2 (0.55) | KMT2AMEN1ALDH1A1HPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124598-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-05-14 | — | — | US | claimed |
| EP-1948190-A2 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | TRANSTECH PHARMA (US) | 2008-07-30 | — | — | EP | claimed |
| WO-2007051810-A2 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | TRANSTECH PHARMA (US) | 2007-05-10 | — | — | WO | claimed |
| US-20090124598-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-05-14 | — | — | US | disclosed |
| US-20090124598-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-05-14 | — | — | US | disclosed |
| US-20090124598-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-05-14 | — | — | US | disclosed |
| EP-1948190-A2 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | TRANSTECH PHARMA (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007051810-A2 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | TRANSTECH PHARMA (US) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124598-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HSD11B1, HSD11B2, HSD3B1 | KMT2A 2957/4885MEN1 2362/4885ALDH1A1 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.